

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	October 15, 2020

DOJOLVI TM (triheptanoin)

LENGTH OF AUTHORIZATION: UP TO ONE YEAR

REVIEW CRITERIA:

- Patient has confirmed diagnosis of long-chain fatty acid oxidation disorders (LC-FAOD)
- Confirm discontinuation of other medium-chain triglyceride (MCT) products prior to use
- Must be prescribed by a clinical specialist knowledgeable in appropriate disease-related dietary management

DOSING AND ADMINISTRATION:

• The recommended target daily dosage of DOJOLVI is up to 35% of the patient's total prescribed daily caloric intake (DCI) divided into at least four doses

$$Total\ Daily\ Dose\ (__mL) = \frac{Patients\ DCI\ (__kcal)\ x\ Target\ ___\%\ dose\ of\ DCI}{8.3\ \frac{kcal}{mL}\ of\ DOJOLVI}$$

DOSAGE FORM:

• 500mL oral solution containing 100% w/w of triheptanoin

